Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus

Abstract Background Pioglitazone as a PPAR-g agonist are used for management of type 2 diabetes mellitus. Nevertheless, evidence showed that the therapeutic modulation of PPARg activity using Pioglitazone may be linked with bone mass reduction and fracture risk in type 2 diabetes mellitus patients. The objective of the current research was to inspect the preventive role of some types of probiotic strains including ( Lactobacillus acidophilus , Lactobacillus reuteri , Lactobacillus casei , Bifidiobacterum longum and Bacillus coagulans ) against pioglitazone-induced bone loss. Methods Streptozotocin (60 mg/kg) was administered for diabetes induction. Diabetic rats were fed orally with pioglitazone (300 mg/kg) and probiotics (1×109 CFU/ml/day) alone and in combination of both for 4 weeks. Dual energy X-ray absorptiometry (DEXA) were used to asses BMD, BMC and area of the femur, spine and tibia at the experiment termination. Serum glucose, serum calcium, alkaline phosphatase, phosphorus, BUN, Creatinine, and urine calcium were also analyzed. Results Administration of pioglitazone and probiotics alone and in combination significantly improved elevated blood glucose. Pioglitazone treatment significantly increased urinary calcium and BUN, and decreased ALP and creatinine. Co-treatment of probiotics with pioglitazone significantly decreased urinary calcium, creatinine and ALP. Pioglitazone showed detrimental effects on femur-BMD whereas treatment with probiotics remarkably ameliorated these effects. Among the tested probiotics Bifidiobacterum longum displayed the best protective effects on pioglitazone-induced bone loss in diabetic rats. Conclusion This study suggests probiotic supplementation in diabetic patients on pioglitazone regime could be considering as a good strategy to ameliorate bone loss induced by pioglitazone.

Download Full-text

Faculty Opinions recommendation of Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726435876.793538284 ◽

2017 ◽

Author(s):

Pablo Aschner

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Randomized Trial ◽

Nonalcoholic Steatohepatitis ◽

Pioglitazone Treatment

Download Full-text

HMG-CoA reductase inhibitors prevent bone loss in patients with Type 2 diabetes mellitus

Diabetic Medicine ◽

10.1111/j.1464-5491.2004.01292.x ◽

2004 ◽

Vol 21 (9) ◽

pp. 1020-1024 ◽

Cited By ~ 18

Author(s):

A. Nakashima ◽

R. Nakashima ◽

T. Ito ◽

T. Masaki ◽

N. Yorioka

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Bone Loss ◽

Hmg Coa Reductase ◽

Prevent Bone Loss ◽

Reductase Inhibitors ◽

Hmg Coa Reductase Inhibitors ◽

Coa Reductase

Download Full-text

Clinical and Radiographic Variables Around Implant With Simultaneous Graft Among Type 2 Diabetic Patients Treated With Different Hypoglycemic Medications: A Retrospective Study.

10.21203/rs.3.rs-134530/v1 ◽

2020 ◽

Author(s):

Shaojie Shi ◽

Feng Ding ◽

Xiangdong Liu ◽

Lei Wang ◽

Xingxing Wang ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Bone Loss ◽

Hypoglycemic Agents ◽

Marginal Bone Loss ◽

Insulin Group ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Abstract Background: The clinical and radiographic variables around dental implants in type 2 diabetes mellitus patients with different hypoglycemic agents still remained unclear.Methods: This retrospective cohort study collected the dental records and digital periapical radiographs of type 2 diabetes mellitus patients and implants. These patients were grouped according to their medication: insulin, metformin, and glucagon-like peptide-1 drugs. The radiographic marginal bone loss around implants and clinical parameters, including peri-implant bleeding on probing and probing depth, were compared among groups using the Kruskal-Wallis test.Results: A total of 150 patients with 308 implants (101 in insulin group, 121 in metformin group and 86 in glucagon-like peptide-1 drugs group) were assessed. The peri-implants marginal bone loss in insulin group (P<0.05) and metformin group (P<0.01) were significantly higher than glucagon-like peptide-1 drug group. The radiographic bone loss in metformin was higher than insulin group (P<0.05). While there was no statistical difference of clinical peri-implant parameters among groups(P>0.05).Conclusions: The radiographic variables were not exactly the same among type 2 diabetes mellitus patients with different hypoglycemic agents. glucagon-like peptide-1 drugs might be more beneficial to bone tissue around implants. More studies are needed to verify the direct effect of these drugs on peri-implant bone.Clinical trial registration number: ChiCTR2000034211 (retrospectively registered)

Download Full-text

Crestal Bone Loss Around Submerged and Non-Submerged Dental Implants in Individuals with Type-2 Diabetes Mellitus: A 7-Year Prospective Clinical Study

Medical Principles and Practice ◽

10.1159/000495111 ◽

2018 ◽

Vol 28 (1) ◽

pp. 75-81 ◽

Cited By ~ 4

Author(s):

Saeed Al Zahrani ◽

Abdullah A. Al Mutairi

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Bone Loss ◽

Dental Implants ◽

Haemoglobin A1c ◽

Crestal Bone Loss ◽

Implant Therapy ◽

The Impact

Objective: In establishing an evidence-based rationale for the optimal use of implant therapy in patients with type 2 diabetes mellitus (T2DM), it is essential to first understand the impact of glycemic control on early healing and the success of dental implants. The objective of this study was to evaluate crestal bone loss (CBL) and stability around submerged and non-submerged dental implants in Saudi patients with well- and poorly controlled T2DM. Subject and Methods: Thirty-five patients with well-controlled T2DM (24 males and 11 females) and 32 poorly controlled T2DM patients (19 males and 13 females) were included. CBL was measured on digital radiographs; resonance frequency analysis (RFA) measurements were made for each implant at the time of fixture placement and at 3 months in both the groups. A p value less than 0.05 was considered statistically significant. Results: A total of 124 dental implants were placed. Mean RFA values between baseline and 3 months in poorly controlled T2DM patients was statistically significant (p = 0.048). CBL at first year (p = 0.047), second year (p = 0.041), third year (p = 0.046), and seventh year (p = 0.035) was significantly worse in poorly controlled T2DM. CBL around non-submerged dental implants showed statistically significant differences at all time-intervals (p < 0.05). Conclusion: Poorly controlled T2DM patients present worse peri-implant bone outcomes as compared to patients with well-controlled T2DM. We suggest that the predictability of successful dental implant therapy outcomes depends on the maintenance of optimal haemoglobin A1c levels.

Download Full-text